Vigil Competitors

Delisted . USA . 
Stock . Vigil Neuroscience
VIGLDelisted Stock  USD 8.05  0.00  0.00%   
Vigil Neuroscience competes with Climb Bio, and Claritev; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Vigil Neuroscience competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Vigil Neuroscience to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Vigil Neuroscience competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
8.058.058.05
Details
Intrinsic
Valuation
LowRealHigh
5.635.638.86
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Vigil Neuroscience. Your research has to be compared to or analyzed against Vigil Neuroscience's peers to derive any actionable benefits. When done correctly, Vigil Neuroscience's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Vigil Neuroscience.

Vigil Neuroscience Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Vigil Neuroscience and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Vigil and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Vigil Neuroscience does not affect the price movement of the other competitor.

High positive correlations

SCPH
+ 0.76
CKPT
SCPH
+ 0.68
YMAB
YMAB
+ 0.6
CLYM
SCPH
+ 0.51
CLYM
YMAB
+ 0.41
CKPT
CLYM
+ 0.34
CKPT
  

High negative correlations

CTEV
- 0.76
YMAB
RVNC
- 0.68
CKPT
SCPH
- 0.54
RVNC
CTEV
- 0.49
CLYM
ITOS
- 0.42
RVNC
CTEV
- 0.41
ITOS

Risk-Adjusted Indicators

There is a big difference between Vigil Stock performing well and Vigil Neuroscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Vigil Neuroscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ORTX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CKPT  2.14  0.93  0.26 (0.64) 1.42 
(2.97)
 2.33 
(2.52)
 62.14 
RVNC  3.04 (0.37) 0.00  0.26  0.00 
 0.00 
 6.38 
(5.97)
 40.39 
GTHX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CLYM  5.89  1.32  0.25  0.74  5.01 
(7.48)
 20.21 
(8.84)
 40.37 
YMAB  4.04  1.35  0.44  0.81  1.80 
(5.58)
 7.03 
(4.29)
 103.46 
SCPH  2.39  0.57  0.17  1.66  2.34 
(2.79)
 7.28 
(4.75)
 17.14 
ITOS  0.39  0.01 (0.11)(0.08) 0.43 
(0.55)
 1.09 
(0.79)
 3.17 
SLGC  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CTEV  5.21 (0.21) 0.00  0.21  0.00 
 0.00 
 10.91 
(13.45)
 37.38 
All Fundamental Data

Vigil Neuroscience Competitive Analysis

The better you understand Vigil Neuroscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Vigil Neuroscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Vigil Neuroscience's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
VIGL CKPT RVNC CLYM YMAB SCPH ITOS CTEV
 0.00 
 8.05 
Vigil
 0.47 
 4.26 
Checkpoint
 0.00 
 3.65 
Revance
 5.00 
 4.41 
Climb
 0.00 
 8.61 
YMAB
 0.18 
 5.67 
Scpharmaceuticals
 0.00 
 10.15 
Iteos
 7.38 
 31.71 
Claritev
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very risky
Very steady
Very steady
Very steady
Not too volatile
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Solid
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Hazard
Hazard
Fair
Hazard
Hazard
Hazard
Risky
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Not Rated
Hold
Not Rated
Not Rated
Not Rated
Strong Sell
Current Ratio
21.35 X
1.30 X
3.38 X
N/A
5.23 X
3.72 X
6.42 X
N/A
Net Asset
117.69 M
7.47 M
478.45 M
217.19 M
119.9 M
107.52 M
686.98 M
5.15 B
Profit Margin
N/A
N/A
(0.72) %
N/A
(0.26) %
(1.84) %
N/A
(0.36) %
EBITDA
(83.8 M)
(56.17 M)
(290.64 M)
(30.36 M)
(30.67 M)
(77.43 M)
(121.82 M)
(1.01 B)
Current Valuation
321.16 M
337.66 M
680.39 M
200.05 M
332.06 M
315.46 M
(61.62 M)
5.14 B
Price To Book
9.11 X
22.75 X
12.30 X
1.62 X
4.47 X
28.45 X
0.91 X
43.86 X
Operating Margin
N/A
N/A
(0.54) %
N/A
(0.29) %
(0.89) %
N/A
0.1 %
Retained Earnings
(307.03 M)
(370.57 M)
(2.08 B)
(229.88 M)
(487.14 M)
(366.49 M)
(9.78 M)
(2.15 B)
Current Asset
N/A
46.85 M
208.68 M
N/A
N/A
N/A
N/A
N/A
Beta
3.34
1.14
0.95
-0.15
0.53
0.3
1.49
0.52
Number Of Employees
67
24
597
17
104
162
173
2.7 K
Shares Outstanding
46.67 M
86.32 M
104.39 M
47.74 M
45.44 M
53.68 M
44.21 M
16.53 M
Cash Flow From Operations
(51.22 M)
(31.1 M)
(216.57 M)
(15.56 M)
(15.71 M)
(70.54 M)
(98.18 M)
107.62 M
Total Debt
12.95 M
20.1 M
478.43 M
532 K
820 K
52.69 M
5.1 M
4.54 B
Return On Equity
-1.46
-18.7
-20.97
-0.26
-0.24
-9.34
-0.35
-6.46
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.62
-1.53
-0.24
-0.17
-0.0867
-0.57
-0.18
0.0096
Number Of Shares Shorted
447.39 K
2.96 M
4.51 M
2.22 M
1.85 M
811.77 K
2.06 M
784.71 K
Book Value Per Share
0.86 X
0.20 X
(1.55) X
2.60 X
1.93 X
(0.40) X
12.90 X
(6.17) X
Current Liabilities
N/A
2.89 M
17.52 M
N/A
N/A
N/A
N/A
N/A
Total Asset
117.69 M
7.47 M
478.45 M
217.19 M
119.9 M
107.52 M
686.98 M
5.15 B
Debt To Equity
0 %
0.1 %
2.94 %
N/A
0.02 %
0.32 %
0.01 %
N/A
Short Ratio
0.56 X
3.18 X
1.70 X
1.15 X
1.00 X
0.36 X
1.34 X
3.31 X
Target Price
8.0
4.45
9.47
9.5
8.6
5.68
10.35
85.0
Shares Owned By Institutions
69.90 %
42.18 %
87.45 %
53.63 %
82.77 %
80.35 %
90.28 %
85.93 %
Market Capitalization
375.71 M
370.71 M
381.02 M
286.37 M
391.22 M
304.36 M
448.68 M
524.03 M
Price To Earning
N/A
(7.60) X
(7.60) X
N/A
N/A
N/A
50.50 X
N/A
Price To Earnings To Growth
N/A
N/A
(0.64) X
N/A
0.04 X
N/A
N/A
N/A
Price To Sales
N/A
9,042 X
1.48 X
N/A
4.58 X
6.09 X
12.78 X
0.55 X
Net Income
(84.26 M)
(56.24 M)
(323.99 M)
(73.9 M)
(29.67 M)
(85.15 M)
(134.41 M)
(1.65 B)
Earnings Per Share
(2.10) X
(1.28) X
(3.34) X
(0.59) X
(0.50) X
(1.81) X
(4.73) X
(20.91) X
Shares Owned By Insiders
18.16 %
14.05 %
8.55 %
0.79 %
11.97 %
5.97 %
0.34 %
6.60 %
Revenue
N/A
41 K
234.04 M
N/A
87.69 M
36.33 M
35 M
930.62 M
Working Capital
66.44 M
(12.62 M)
249.64 M
149.94 M
74.81 M
90.97 M
469.18 M
(38.27 M)
Cash And Equivalents
148.91 M
30.89 M
233.82 M
N/A
133.66 M
55.85 M
791.86 M
N/A
Cash Per Share
5.27 X
0.33 X
3.20 X
N/A
3.06 X
2.04 X
22.26 X
N/A
Gross Profit
N/A
(31.4 M)
103.69 M
N/A
69.58 M
34.21 M
N/A
710.55 M
Day Typical Price
8.05
4.26
3.65
4.34
8.61
5.68
10.15
30.89
Accumulation Distribution
N/A
0.0117
N/A
0.0476
N/A
0.0105
N/A
0.11
Market Facilitation Index
N/A
0.05
N/A
0.21
N/A
0.06
N/A
3.49
Daily Balance Of Power
0.0
0.4
0.0
1.0
0.0
(0.17)
0.0
0.6246
Period Momentum Indicator
N/A
0.02
N/A
0.21
N/A
(0.01)
N/A
2.18
Rate Of Daily Change
1.0
1.0
1.0
1.05
1.0
1.0
1.0
1.07
Day Median Price
8.05
4.26
3.65
4.31
8.61
5.68
10.15
30.49
Price Action Indicator
N/A
0.015
N/A
0.21
N/A
(0.01)
N/A
2.32
Coefficient Of Variation
834.85
905.43
(1,353)
564.52
887.46
598.35
3829.2
(2,466)
Mean Deviation
7.5
2.14
3.04
5.89
4.04
2.39
0.3865
5.21
Jensen Alpha
3.15
0.9301
(0.37)
1.32
1.35
0.5717
0.0094
(0.21)
Total Risk Alpha
1.0
0.1815
(1.05)
0.7391
0.3414
0.2843
(0.04)
(0.93)
Sortino Ratio
0.8139
0.2617
N/A
0.2475
0.4357
0.1661
(0.11)
N/A
Downside Variance
18.49
8.96
N/A
31.04
10.29
10.22
0.263
N/A
Standard Deviation
29.83
7.76
6.54
8.2
13.05
3.62
0.58
7.31
Kurtosis
64.74
58.48
15.23
2.76
59.45
2.75
2.23
1.72
Potential Upside
5.09
2.33
6.38
20.21
7.03
7.28
1.09
10.91
Treynor Ratio
0.5461
(0.64)
0.2581
0.7445
0.8144
1.66
(0.08)
0.2069
Maximum Drawdown
241.38
62.14
40.39
40.37
103.46
17.14
3.17
37.38
Variance
889.72
60.16
42.72
67.2
170.4
13.08
0.3364
53.45
Market Risk Adjusted Performance
0.5561
(0.63)
0.2681
0.7545
0.8244
1.67
(0.07)
0.2169
Risk Adjusted Performance
0.0985
0.0909
(0.05)
0.1404
0.0929
0.1318
0.0166
(0.02)
Skewness
8.01
7.39
(2.30)
1.43
7.53
0.8455
0.8396
(0.94)
Semi Deviation
1.63
1.42
N/A
5.01
1.8
2.34
0.4282
N/A
Information Ratio
0.1173
0.101
(0.09)
0.1682
0.107
0.1468
(0.10)
(0.05)
Value At Risk
(2.49)
(2.52)
(5.97)
(8.84)
(4.29)
(4.75)
(0.79)
(13.45)
Expected Short fall
(9.75)
(2.97)
N/A
(7.48)
(5.58)
(2.79)
(0.55)
N/A
Downside Deviation
4.3
2.99
N/A
5.57
3.21
3.2
0.5128
N/A
Semi Variance
2.66
2.03
N/A
25.15
3.23
5.48
0.1833
N/A

Vigil Neuroscience Competition Performance Charts

Five steps to successful analysis of Vigil Neuroscience Competition

Vigil Neuroscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Vigil Neuroscience in relation to its competition. Vigil Neuroscience's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Vigil Neuroscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Vigil Neuroscience's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Vigil Neuroscience, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Vigil Neuroscience position

In addition to having Vigil Neuroscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Exotic Funds Thematic Idea Now

Exotic Funds
Exotic Funds Theme
Funds or Etfs with high minimum investment requirement that manage portfolios of alternative investments such as hedge funds, options, futures, real estate or commodities. The Exotic Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Exotic Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Other Consideration for investing in Vigil Stock

If you are still planning to invest in Vigil Neuroscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vigil Neuroscience's history and understand the potential risks before investing.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY